Abstract While a dominant inheritance of breast cancer (vertical inheritance) is well known, less is known about a possible recessive inheritance (horizontal inheritance). In a clinical series of 1676 breast cancer patient's family history was scored as vertical (grandmother-aunt-mother-sisterdaughter) or horizontal (sister-sister) and related to histopathological tumor type, presence of germline mutations, bilaterality, multifocality, screening, parity, hormone replacement therapy (HRT) use and age at diagnosis. Prognosis was estimated by also adding tumor size, lymph node status, distant metastases and hormone receptor status at diagnosis into a Cox proportional hazard model.
Introduction
Twin studies suggest that most familial aggregation in breast cancer results from inherited susceptibility [1, 2] . BRCA1, BRCA2 and other known susceptibility genes account for approximately 20% of this effect [3] , the highsusceptibility genes (such as PTEN, STK11, TP53) together with moderate-susceptibility (such as CHK2, ATM, PALB2, BRIP1) account for around 2%, whereas approximately 4% is credited to the low-susceptibility genes (such as FGFR2, TOX3, MAP3K1, LSP1) [4, 5] , this leaves approximately 75% of all familial breast cancer unexplained.
While a dominant inheritance of breast cancer (vertical inheritance) is well known, less is known about a possible recessive inheritance (horizontal inheritance). With the exception of rare syndromes like Ataxia-Telangiectasia, where homozygote and heterozygote carriers have an increased risk for breast cancer, it has been more difficult to identify recessive genes for breast cancer [6] . However, a number of segregation analyses have raised the possibility of an existence of a recessive gene [7] [8] [9] [10] [11] . Additionally, a recent study from Scotland found a higher risk for breast cancer in sisters than other relatives in high risk families suggesting the possibility of a recessive inheritance [12] .
We have previously in a preliminary report described a possible relationship between lobular breast cancer, late age at diagnosis and a horizontal inheritance [13] . In the -39  132  8  42  11  0  0   40-49  401  24  114  30  11  13   50-59  448  27  101  27  22  26   60-69  420  25  80  21  22  26   70-79  225  13  34  9  24  29   80-89  35  2  3  1  4  5   Tumor stage   0  84  5  21  6  4  5   I  462  28  133  35  17  20   II  678  40  123  32  39  46  III  366  22  83  22  16  19   IV  28  2  4  1 present study we have investigated whether tumor biology, tumor histology and some breast cancer risk factors are related to a horizontal versus a vertical inheritance/family history of breast cancer, aimed at defining a candidate phenotype for a recessive inheritance. In the present study, patients with the strongest family history (often vertical) were offered genetic screening for BRCA1, BRCA2, TP53 and CDKN2A. In further analyses mutation carriers of these genes were separately analyzed to allow us to investigate a family setting without the strong dominant genes.
Materials and methods
In a clinical series of 1676 breast cancer patients (median age 56, range 23-89) family history of breast cancer was scored as vertical (grandmother-aunt-mother-sister-daughter), horizontal (sister-sister), or none and related to histopathological tumor type, presence of germline mutations, bilaterality, multifocality, screening, parity, hormone replacement therapy (HRT) and age at diagnosis. Families that both had a horizontal and a vertical disease transmission were scored as vertical. After excluding germline mutation carriers of BRCA1, BRCA2, TP53 and CDKN2A, only breast cancer was considered in the family history. Due to lack of information concerning HER-2/neu and histologic grade, more than 70% missing, they were not considered in any calculations. Pathological slides were not re-examined, and the diagnosis determining treatment was used. Besides retrieving information from hospital records and pathological reports, patients underwent a standardized oral interview concerning family history, environmental/reproductive risk factors, screening history and patient delay. Information from our population-based cancer registry and Population Registry in Sweden was used for finding new incident contralateral breast cancer as well as date of diagnosis, death and confirming diagnosis of relatives.
The Department of Oncology, University Hospital, Lund has a population-based catchment area, serving the Southern Health Care region in Sweden with adjuvant and metastatic treatment of breast cancer. Follow-up of the patients was performed until Jan 1, 2009.
Families with three affected breast or ovarian cancer cases with at least one diagnosed before age 50, families with two affected breast or ovarian cancer cases with at least one diagnosed before age 40 and single patients diagnosed with breast cancer before age 30 have been offered genetic counseling and mutation screening according to the national cancer care program of Sweden.
Binary logistic regression was used to estimate factors associated with horizontal versus vertical inheritance. As a control group for the histopathological groups a combined group of mixed histopathologies, undefined adenocarcinomas and other rare tumors was used. Odds ratios (OR) were estimated with 95% CI.
Prognosis was estimated by adding tumor size, lymph node status, distant metastases and hormone receptor status at diagnosis into a Cox proportional hazard model adjusting for age at diagnosis, risk factors and tumor biology factors simultaneously. Hazard ratio (HR) was estimated using a 95% CI.
Results
During follow-up 856 patients (48.5%) died, the median follow-up time was 15 years, range 0.5-29 years. Around 4% of the cases were mutation screened according to the screening criteria. A vertical family history was present in 23% and a horizontal in 5% of the cases. A multifocal and bilateral tumor was present in 10% respectively. Seventeen percent were nulliparous at diagnosis and median number of children were 2 (range 0-9). Ever users of HRT were 18.8%. Estrogen receptor (ER) status was known for 65% (68% ER-positive, 32% ER-negative), Progesterone receptor (PgR) status for 63% (58%PgR-positive, 42% PgR-negative) ( Table 1) . Germline mutation carriers added up to 16 (0.95%) in total; 9 (0.89%) BRCA1, 5 (0.5%) BRCA2, CDKN2A and TP53 1 (0.10%) respectively, none of which were present in tubular or mucinous breast cancer.
The median tumor size was 20 mm (range 3-503 mm). Forty-four percent were node negative.
Pure ductal, lobular, tubular, medullary, mucinous cancers were present in 41, 8.5, 2.6, 1.8, and 1.5% respectively, a mixture of or very rare histopathological types were present in 36.7%. In situ cancers constituted 8%.
In the following analyses mixed tumor types, very rare tumor types and non-invasive cancers were excluded if not stated otherwise.
Excluding mutation carriers, but including non-invasive cancers, the following factors were significantly related to a horizontal family history: tubular tumor type [OR (Table 2) .
No significant difference in survival could be seen between patients with no, horizontal or vertical family history, however, germline mutation carriers had a significantly worse survival. (Fig. 1 ) Screening detected cases, HRT-ever users, patients with ER-positive tumors had a significantly better survival adjusting for age at diagnosis, tumor size, lymph node status and presence of distant metastases at diagnosis (Table 3 ). The reason why the survival of germline mutations is only displayed for 180 months and not the full 350 months is that genetic screening started in 1994. Therefore, the follow-up is only 15 of the 29 years for germline mutation carriers.
Discussion
The main finding in this study was that a vertical family history was associated to multifocality and more often occurred in breast cancer patients detected via screening, while a horizontal family history was associated to patients with tubular breast cancer.
The association between higher age at diagnosis and horizontal family history can be explained by that it is most likely easier to find a patient with vertical family history at an earlier age compared to finding a patient with horizontal family history as the mother/grandmother of the patient with a vertical inheritance would be older and having a higher risk by age at developing breast cancer then a potential sister of a patient with a horizontal inheritance and thereby pin pointing the family pattern. In a similar manner multifocality is easier detected in families with Fig. 1 a Survival for mutation carriers (dotted line) compared to all others (whole line). The model was adjusted for age at diagnosis, tumor size, number of positive lymph nodes, and occurrence of distant metastases. b Survival for patients with a horizontal family history (dotted line) compared to all others (whole line). The model was adjusted for age at diagnosis, tumor size, number of positive lymph nodes, and occurrence of distant metastases vertical family histories versus horizontal family histories. Therefore, since most studies aimed at finding hereditary breast cancer are focused on cases diagnosed at a young age they would subsequently miss cases with recessive inheritance occurring in an older population. This is also true for some registry-based studies, such as results from the Swedish Multigeneration Registry linked to the Cancer registry and not incorporating cases older than 62 years of age.
Another striking observation is the strong association between a horizontal family pattern and tubular breast cancer. Tubular breast cancer is a rare tumor type constituting around 1-5% of all breast cancer and have been studied in relationship to family history [14] . A relationship was found, but the finding was within the range of chance, which probably was due to small the number of cases in the study. However, an old publication from 1980 inferred an overall relationship between tubular breast cancer and familiarity [15] . Our data, also looking at inheritance pattern, suggest that indeed patients with tubular breast cancer have a strong family history and could be a candidate phenotype for recessive inheritance.
Survival did not differ between patients having a horizontal versus a vertical family tree with breast cancer. The small group of mutation carriers did however have a worse survival. Conventional prognostic factors such as large tumor size, tumor involved lymph node status, distant metastases and low estrogen receptor content showed, as expected, a worse prognosis. In line with most previous findings HRT ever users had a better prognosis [16, 17] , while screening detected cases had a better prognosis, again in line with literature [18] .
Patients are referred in a population based setting from the entire Southern Health Care Region to the Department of Oncology at Lund University Hospital since it is responsible for radio-and chemotherapy in that area. As the case series here was slightly younger than the mean age in the cancer registry some older cases and cases only operated without adjuvant therapy (stage I) may not be referred. Overall we receive around 60% of all breast cancer cases for therapy. Therefore our results may not fully be applicable to stage I or more, and older patients.
In the present study we have not been able to study the histopathological tumor types of relatives to see if there is a concordance in diagnosis between family members. Likewise bilateral tumor cases need to be studied among familial cases in order to find out if there is a relationship between the primary tumor and the contralateral tumor.
We choose only to study pure histopathological groups and used patients with mixed histologies as a part of the control group, therefore we cannot make any statements regarding possible relationships between individuals with mixed histologies and inheritance. Can a phenotype for recessive inheritance in breast cancer be defined? 529 Summary A possible phenotype for recessively inherited breast cancer has been described encompassing patients with sistersister family history of breast cancer, displaying the tumor type tubular. Another feature of these families is a higher age at diagnosis compared with breast cancer families with a dominant inheritance pattern. The phenotype is not significantly associated with a worse survival.
